Clinical trials: Asthma Patients
Allergy
Efficacy of SLITone in House Dust Mite Allergic Patients
This trial has been designed to evaluate the efficacy of specific immunotherapy with SLITone Dermatophagoides mix compared with placebo in subjects with house dust mite allergic asthma, based on asthma medication use during a…
- Trial name
- NCT00633919
- Testing
- SLITone(TM) Dermatophagoides mix, Salbutamol inhaler, Budesonide/formoterol inhaler
- Where
- Spain
- Volunteers
- 124 people
- Sponsor
- ALK-Abelló A/S
Severe Asthma
Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium
This study aims to assess health and quality of life outcomes in patients treated with benralizumab, within a Belgian Real-World setting.
- Trial name
- BE-REAL (NCT04221802)
- Where
- 10 sites in Belgium
- Volunteers
- 76 people
- Sponsor
- AstraZeneca
Asthma
Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled LAS100977 QD in patients with persistent asthma.
- Trial name
- NCT01425801
- Testing
- LAS100977 0.313 μg, LAS100977 0.625 μg, LAS100977 1.25 μg
- Where
- 9 sites in Germany, United Kingdom
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Asthma
Control of Asthma Patients Symptomatic on Inhaled Corticosteroids
The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.
- Trial name
- NCT00330070
- Testing
- IPL512,602 20 mg once daily
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- Inflazyme Pharmaceuticals Ltd
Moderate to Severe Allergic Asthma
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to assess the therapeutic potential and safety/tolerability of study drug (CYT003) at 3 dose levels versus placebo in patients with persistent moderate to severe allergic asthma not sufficiently…
- Trial name
- NCT01673672
- Testing
- CYT003
- Where
- 34 sites in United States, Czechia and 6 more
- Volunteers
- 365 people
- Sponsor
- Cytos Biotechnology AG
Asthma
Asthma Biomarker Study
The main objective of the trial is to explore if any of the biomarkers assessed are sensitively linked to the asthma phenotypes.
- Trial name
- NCT02392481
- Testing
- Biofluid sampling
- Where
- 4 sites in United Kingdom
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Aspirin Exacerbated Respiratory Disease (AERD)
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
The primary objective of the study is to determine the safety of oral ifetroban compared to placebo as measured by a > 20% decrease in FEV1 compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study…
- Trial name
- NCT02216357
- Testing
- Ifetroban, Oral Capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Cumberland Pharmaceuticals
Perennial Allergic Rhinitis Accompanied by Asthma
Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma
This study aims to compare the efficacy and safety of DW1807 and DW1807-R2 in patients with perennial allergic rhinitis and comorbid asthma.
- Trial name
- NCT07168473
- Testing
- Experimental, Comparator
- Where
- South Korea
- Volunteers
- 274 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Respiratory Syncytial Virus Bronchiolitis
Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
This is a prospective, multicenter, observational study in participants who completed the 24-week, placebo-controlled MK-0476 Protocol 272 (NCT00076973) study of montelukast in the treatment of respiratory symptoms subsequent to…
- Trial name
- NCT01140048
- Volunteers
- 343 people
- Sponsor
- Organon and Co
Persistent Allergic Asthma
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
This study will evaluate the effect of omalizumab on markers of impairment in patients with inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in the 2007 National Heart, Lung, and Blood…
- Trial name
- NCT00870584
- Testing
- Omalizumab
- Where
- 50 sites in United States
- Volunteers
- 271 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
- Trial name
- NCT01928771
- Testing
- Benralizumab
- Where
- 275 sites in United States, Australia and 15 more
- Volunteers
- 2,681 people
- Sponsor
- AstraZeneca
Moderate-to-Severe Asthma
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
This is a Prospective, Observational, Multicentre Study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China. Sponsor by Astrazeneca Investment(China) Co., LTD.
- Trial name
- PRESENT (NCT06422663)
- Where
- 31 sites in China
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Asthma
Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.
The main objective of this study is to evaluate the efficacy and safety of the Armstrong's Epinephrine HFA-MDI (E004) formulation, in comparison to the Placebo (Placebo-HFA) and an Active Control (Epinephrine CFC-MDI), and to…
- Trial name
- NCT01025648
- Testing
- E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Severe Asthma
ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab
This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical…
- Trial name
- ANANKE (NCT04272463)
- Testing
- No intervention
- Where
- 18 sites in Italy
- Volunteers
- 217 people
- Sponsor
- AstraZeneca
Asthma
A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma
This study is a multicenter, prospective, observational cohort study of ~5000 Xolair-treated and ~2500 non-Xolair-treated patients with moderate to severe persistent asthma and a positive skin test or in vitro reactivity to an…
- Trial name
- NCT00252135
- Volunteers
- 8,023 people
- Sponsor
- Genentech, Inc.
Asthma
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma
The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult…
- Trial name
- NCT00393952
- Testing
- Fluticasone propionate/Formoterol fumarate 250/10, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- SkyePharma AG
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale
Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5.
- Trial name
- STRENGTH (NCT06678191)
- Testing
- BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
- Where
- 45 sites in Hungary
- Volunteers
- 800 people
- Sponsor
- Chiesi Hungary Ltd.
Cough-Variant Asthma
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
This is a multicenter, prospective, single-arm, interventional clinical study to predict the response to budesonide-formoterol treatment in patients with chronic dry or nocturnal cough by determining a cut off value of FeNO.
- Trial name
- EFFICIENCY (NCT06590740)
- Testing
- Budesonide-Formoterol treatment
- Where
- 39 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma
The Comparison of Electronic Auscultation Coupled With CALSA and FRI; Repeatability of FRI Biomarkers
CALSA will be compared with FRI and the repeatability of the FRI parameters will be tested in a group of healthy volunteers and asthma patients.
- Trial name
- NCT02228018
- Testing
- CT-scan
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- FLUIDDA nv
Asthma
Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma
The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.
- Trial name
- NCT00096616
- Testing
- Combivent® CFC MDI, Albuterol HFA MDI
- Where
- 27 sites in United States
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim